Tinzaparin sodium

Drug Profile

Tinzaparin sodium

Alternative Names: Innohep; Logiparin

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Pharma; Novo Nordisk
  • Developer LEO Pharma
  • Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis

Most Recent Events

  • 09 May 2017 LEO Pharma completes a phase II trial in Thrombosis in France (SC) (NCT02260414)
  • 07 Oct 2016 Additional efficacy data from the phase III CATCH trial in Thrombosis presented at the 41st European Society for Medical oncology Congress (ESMO-2016)
  • 01 May 2014 LEO Pharma completes a long-term phase III global trial in Thrombosis (Prevention of recurrence of venous thromboembolism in cancer patients) (NCT01130025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top